Darryl Geddes 315 464-4828
SUNY Upstate drug study seeks people with ulcerative colitis
SYRACUSE, N.Y. – A clinical trial under way at SUNY Upstate Medical University is testing the effectiveness of a new drug therapy for people diagnosed with ulcerative colitis.
Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the large intestine. The inflammation usually occurs in the rectum and lower part of the colon, but it may affect the entire colon. Symptoms, depending on the severity of the disease, can include bloody diarrhea, abdominal cramps, weight loss and fatigue.
Ulcerative colitis is a chronic illness and can be treated with a variety of drug therapies. The only known cure for the disease is surgical removal of the affected part of the colon.
The clinical study, being conducted by Philip Holtzapple, M.D., professor of medicine at SUNY Upstate, will test the effectiveness of encapsulated mesalamine pellets for the maintenance or remission from mild to moderate ulcerative colitis.
The study is comparing the investigational medication to placebo in people who have been diagnosed with ulcerative colitis that is in remission. To qualify, participants must be at least 18 and in remission from ulcerative colitis for at least one month but no longer than 12 months.
For information on enrolling in the study, contact Karyn Kushner at 464-5794.
Search Upstate News
Upstate in the News
- Parents urged to practice crib safety
News 10 Now
- Upstate Medical University opens new Neuroscience Research Building Monday
WSYR TV9 Syracuse
- Nosebleeds seldom need invasive treatment
- Cuomo: SUNY Upstate Medical University in Syracuse, other upstate schools win $2 million NIH grant
- NIH announced $2 million grant
News 10 Now
- SUNY Upstate Medical University leads six-school partnership that wins $2 million grant
Syracuse Post Standard